Pre-Market: 9:07AM EST
|Bid||29.98 x 28000|
|Ask||29.99 x 41800|
|Day's Range||29.11 - 29.75|
|52 Week Range||23.17 - 29.75|
|Beta (3Y Monthly)||0.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Feb 20 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday: ** Britain's competition regulator has dealt a potentially fatal blow to Sainsbury's planned ...
Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.
The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday. To win approval for the $2 billion deal, the companies agreed to sell NxStage's bloodline tubing set business, the agency said. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency said.
NxStage Medical Inc NASDAQ/NGS:NXTMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for NXTM with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting NXTM. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NXTM totaled $1.90 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
An aging population, prevalence of chronic health conditions and greater utilization of healthcare services should drive the industry's growth, partly offset by an increase in expenses.
Germany's Fresenius Medical Care (FMC) said on Tuesday it had agreed to extend the deadline for its planned $2 billion takeover of U.S. home dialysis equipment maker NxStage Medical Inc until August 6. FMC said the extension had been agreed due to the recent U.S. government shutdown which interrupted the Federal Trade Commission's (FTC) ability to review the transaction.
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
After several tireless days we have finished crunching the numbers from the more than 700 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30. The results of that effort will be put on display in this […]
NxStage (NXTM) delivered earnings and revenue surprises of 150.00% and 0.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NxStage (NXTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
"We are really beginning to see a shift toward using innovative telehealth solutions to help improve patient outcomes with home dialysis," said Dr. Michael Kraus, Associate Chief Medical Officer for NxStage. "Nx2me is an intuitive tool to support and proactively engage with home hemodialysis patients. A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets.
Patients 20-44 years of age experienced 44% lower risk of death LAWRENCE, Mass. , Oct. 23, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing ...